Try our mobile app

Switch to company model in classical logic    *

General information

Country: UNITED STATES

Sector: Drug Manufacturers — Specialty and Generic

Neurocrine Biosciences, Inc. is focused on the discovery and development of therapeutics for neuropsychiatric, neuroinflammatory, and neurodegenerative diseases and disorders. The Company is developing therapeutic interventions for anxiety, depression, alzheimer"s disease, insomnia, stroke, malignant brain tumors, multiple sclerosis, obesity, and diabetes.
Website: neurocrine.com



Growth: Good revenue growth rate 25.0%, there is acceleration compared to average historical growth rates 22.5%. The revenue growth dynamics is moderately stable

Profitability: LTM EBITDA margin is positive, +22.4%. On average the margin is improving unsteadily. Gross margin is high, +98.4%. In the last quarter the company did not beat the estimated EPS. The company was ahead of estimated EPS in 0% of quarters (showing a gain of -$0.46 per share on average)

Cash Flow Generation: Dividend yield for the last twelve months 0.0%. Free cash flow yield -6.8% (LTM)

Undervaluation: Fundamental value created in LTM (estimate)


Entry Point: Share price is 90.1% higher than minimum and 4.2% lower than maximum for the last 3 years

AI Insight: the companies with similar growth trajectories, EBITDA margin, industries and geography on average are valued 3.8x by EV / Sales multiple , the company can be 46.8% overvalued

Insiders: For the last 3 months insiders sold company shares on $44.5 mln (-0.338% of cap.)

Key Financials (Download financials)

Ticker: NBIX
Share price, USD:  (-0.9%)137.76
year average price 115.72  


year start price 101.90 2023-04-27

min close price 89.53 2023-05-31

max close price 143.74 2024-03-21

current price 137.76 2024-04-26
Common stocks: 95 800 000

Dividend Yield:  0.0%
FCF Yield LTM: -6.8%
EV / LTM EBITDA: 31.7x
EV / EBITDA annualized: 11.8x
Last revenue growth (y/y):  25.0%
Last growth of EBITDA (y/y):  110.3%
Historical revenue growth:  22.5%
Historical growth of EBITDA:  23.4%
EV / Sales: 7.1x
Margin (EBITDA LTM / Revenue): 22.4%
Fundamental value created in LTM:
Market Cap ($m): 13 197
Net Debt ($m): 177
EV (Enterprise Value): 13 374
Price to Book: 6.0x

Revenue and EBITDA

Quarterly values ($m)

Change (y/y)

Cash Flow

FCF ($m)

Net Debt / Cash and Equivalents ($m)

Share price and dividends (Download history)

Share price

Payment USD per share

Multiple and potential

EV / Sales

Potential dynamics

News


2024-02-10Seeking Alpha

Neurocrine Biosciences Heads Into A Catalyst-Rich 2024 With Additional Upside

2024-02-07Zacks Investment Research

Neurocrine (NBIX) Q4 Earnings: Taking a Look at Key Metrics Versus Estimates

2024-01-31Zacks Investment Research

Neurocrine Biosciences (NBIX) Earnings Expected to Grow: Should You Buy?

2023-12-26Zacks Investment Research

Neurocrine (NBIX) Soars 6.0%: Is Further Upside Left in the Stock?

2023-11-30Seeking Alpha

Neurocrine Biosciences: Fear Not The IRA

2023-11-10Market Watch

Neurocrine Biosciences shares drop as trial failures may ‘stunt momentum,' analysts say

2023-10-31Seeking Alpha

Neurocrine Biosciences, Inc. (NBIX) Q3 2023 Earnings Call Transcript

2023-10-31Zacks Investment Research

Neurocrine Biosciences (NBIX) Q3 Earnings Miss Estimates

2023-10-11Seeking Alpha

Neurocrine's Crinecerfont Delivered, But The Street Has Been Slow To Reward The Success

2023-10-03Zacks Investment Research

Neurocrine (NBIX) is an Incredible Growth Stock: 3 Reasons Why
More information for subscribed users:
detailed calculation of
Fundamental value created in LTM

Financial reporting

Income Statement

Property 2023 q4 2023 q3 2023 q2 2023 q1 2022 q4 2022 q3
date 2023-12-31 2023-09-30 2023-06-30 2023-03-31 2022-12-31 2022-09-30
symbol NBIX NBIX NBIX NBIX NBIX NBIX
reportedCurrency USD USD USD USD USD USD
cik 914 475 914 475 914 475 914 475 914 475 914 475
fillingDate 2024-02-09 2023-10-31 2023-08-01 2023-05-03 2023-02-09 2022-11-01
acceptedDate 2024-02-09 17:29:13 2023-10-31 07:02:45 2023-08-01 07:03:07 2023-05-03 07:34:21 2023-02-09 16:02:45 2022-11-01 16:10:37
calendarYear 2023.000 2023.000 2023.000 2023.000 2022.000 2022.000
period Q4 Q3 Q2 Q1 Q4 Q3
revenue 515M 499M 453M 420M 412M 388M
costOfRevenue 9M 11M 12M 9M 8M 6M
grossProfit 507M 488M 441M 412M 404M 382M
grossProfitRatio 0.984 0.978 0.975 0.980 0.981 0.984
researchAndDevelopmentExpenses 138M 142M 146M 140M 118M 108M
generalAndAdministrativeExpenses 0 0 0 0 0 0
sellingAndMarketingExpenses 0 0 0 0 0 0
sellingGeneralAndAdministrativeExpenses 219M 204M 222M 243M 183M 186M
otherExpenses 0 0 0 144M 23M 0
operatingExpenses 356M 346M 368M 382M 301M 294M
costAndExpenses 365M 358M 379M 391M 309M 300M
interestIncome 20M 16M 0 0 0 0
interestExpense 1M 1M 1M 1M 1M 1M
depreciationAndAmortization 6M 6M 5M 144M 4M 4M
ebitda 156M 141M 74M 30M 103M 92M
ebitdaratio 0.303 0.283 0.163 0.071 0.251 0.237
operatingIncome 150M 141M 74M -114M 103M 88M
operatingIncomeRatio 0.292 0.283 0.163 -0.272 0.251 0.226
totalOtherIncomeExpensesNet 49M -25M 49M 11M 15M 10M
incomeBeforeTax 198M 116M 122M -103M 118M 98M
incomeBeforeTaxRatio 0.385 0.232 0.269 -0.246 0.286 0.252
incomeTaxExpense 51M 33M 26M -27M 29M 29M
netIncome 148M 83M 96M -77M 89M 69M
netIncomeRatio 0.287 0.167 0.211 -0.182 0.216 0.177
eps 1.500 0.850 0.980 -0.790 0.920 0.720
epsdiluted 1.440 0.820 0.950 -0.790 0.880 0.690
weightedAverageShsOut 98M 98M 98M 97M 96M 96M
weightedAverageShsOutDil 102M 101M 100M 97M 101M 99M
link Link Link Link Link Link Link
finalLink Link Link Link Link Link Link

Balance Sheet Statement

Property 2023 q4 2023 q3 2023 q2 2023 q1 2022 q4 2022 q3
date 2023-12-31 2023-09-30 2023-06-30 2023-03-31 2022-12-31 2022-09-30
symbol NBIX NBIX NBIX NBIX NBIX NBIX
reportedCurrency USD USD USD USD USD USD
cik 914 475 914 475 914 475 914 475 914 475 914 475
fillingDate 2024-02-09 2023-10-31 2023-08-01 2023-05-03 2023-02-09 2022-11-01
acceptedDate 2024-02-09 17:29:13 2023-10-31 07:02:45 2023-08-01 07:03:07 2023-05-03 07:34:21 2023-02-09 16:02:45 2022-11-01 16:10:37
calendarYear 2023.000 2023.000 2023.000 2023.000 2022.000 2022.000
period Q4 Q3 Q2 Q1 Q4 Q3
cashAndCashEquivalents 251M 294M 160M -90M 263M 212M
shortTermInvestments 781M 801M 817M 1 139M 726M 587M
cashAndShortTermInvestments 1 032M 1 095M 977M 895M 989M 799M
netReceivables 439M 418M 388M 392M 350M 301M
inventory 38M 29M 32M 33M 35M 37M
otherCurrentAssets 98M 555M 520M 538M 464M 68M
totalCurrentAssets 1 607M 1 650M 1 497M 1 433M 1 454M 1 206M
propertyPlantEquipmentNet 347M 150M 149M 147M 146M 151M
goodwill 6M 0 0 0 0 0
intangibleAssets 36M 35M 37M 37M 37M 0
goodwillAndIntangibleAssets 36M 35M 37M 37M 37M 0
longTermInvestments 849M 588M 516M 380M 402M 458M
taxAssets 363M 383M 379M 337M 306M 319M
otherNonCurrentAssets 50M 43M 36M 25M 25M 11M
totalNonCurrentAssets 1 644M 1 198M 1 117M 927M 915M 938M
otherAssets 0 0 0 0 0 0
totalAssets 3 251M 2 848M 2 613M 2 360M 2 369M 2 143M
accountPayables 109M 94M 0 0 76M 0
shortTermDebt 170M 170M 170M 0 169M 169M
taxPayables 24M 73M 0 0 0 0
deferredRevenue 340M -94M 0 0 0 0
otherCurrentLiabilities 36M 522M 413M 374M 292M 316M
totalCurrentLiabilities 655M 692M 583M 374M 538M 485M
longTermDebt 258M 86M 89M 260M 94M 97M
deferredRevenueNonCurrent -79M 0 0 0 0 0
deferredTaxLiabilitiesNonCurrent 79M 0 0 0 0 0
otherNonCurrentLiabilities 106M 69M 89M 41M 30M -56M
totalNonCurrentLiabilities 365M 155M 178M 301M 123M 114M
otherLiabilities 0 0 0 0 0 0
capitalLeaseObligations 258M 86M 89M 90M 94M 97M
totalLiabilities 1 019M 846M 760M 675M 661M 599M
preferredStock 0 0 0 0 0 0
commonStock 100 000 100 000 100 000 100 000 100 000 100 000
retainedEarnings -157M -305M -388M -483M -407M -496M
accumulatedOtherComprehensiveIncomeLoss 7M -2M -1M -3M -8M -14M
othertotalStockholdersEquity 2 382M 2 309M 2 242M 2 171M 2 122M 2 054M
totalStockholdersEquity 2 232M 2 002M 1 853M 1 685M 1 708M 1 545M
totalEquity 2 232M 2 002M 1 853M 1 685M 1 708M 1 545M
totalLiabilitiesAndStockholdersEquity 3 251M 2 848M 2 613M 2 360M 2 369M 2 143M
minorityInterest 0 0 0 0 0 0
totalLiabilitiesAndTotalEquity 3 251M 2 848M 2 613M 2 360M 2 369M 2 143M
totalInvestments 1 630M 934M 990M 1 139M 1 128M 1 045M
totalDebt 428M 256M 259M 260M 263M 266M
netDebt 177M -38M 99M 350M 0 54M
link Link Link Link Link Link Link
finalLink Link Link Link Link Link Link

Cash Flow Statement

Property 2023 q4 2023 q3 2023 q2 2023 q1 2022 q4 2022 q3
date 2023-12-31 2023-09-30 2023-06-30 2023-03-31 2022-12-31 2022-09-30
symbol NBIX NBIX NBIX NBIX NBIX NBIX
reportedCurrency USD USD USD USD USD USD
cik 914 475 914 475 914 475 914 475 914 475 914 475
fillingDate 2024-02-09 2023-10-31 2023-08-01 2023-05-03 2023-02-09 2022-11-01
acceptedDate 2024-02-09 17:29:13 2023-10-31 07:02:45 2023-08-01 07:03:07 2023-05-03 07:34:21 2023-02-09 16:02:45 2022-11-01 16:10:37
calendarYear 2023.000 2023.000 2023.000 2023.000 2022.000 2022.000
period Q4 Q3 Q2 Q1 Q4 Q3
netIncome 148M 83M 96M -77M 89M 69M
depreciationAndAmortization 6M 6M 5M 5M 4M 4M
deferredIncomeTax 21M -4M -42M -32M 14M 9M
stockBasedCompensation 38M 48M 69M 40M 44M 43M
changeInWorkingCapital -54M 46M 93M -58M -2M -16M
accountsReceivables -21M -30M 4M -42M -47M -22M
inventory -900 000 3M 2M 2M 4M -8M
accountsPayables -83M 124M 16M 7M 115M 0
otherWorkingCapital 52M -51M 71M -24M -74M 14M
otherNonCashItems -35M 34M -41M -4M -6M -10M
netCashProvidedByOperatingActivities 124M 212M 180M -125M 143M 99M
investmentsInPropertyPlantAndEquipment -5M -8M -7M -9M -2M 0
acquisitionsNet 5M 90M 7M -2M -43M 0
purchasesOfInvestments -487M -363M -324M -238M -233M -134M
salesMaturitiesOfInvestments 291M 273M 205M 204M 162M 71M
otherInvestingActivites -5M -90M -7M 2M 0 2M
netCashUsedForInvestingActivites -202M -97M -126M -42M -116M -61M
debtRepayment 0 0 0 0 -279M 0
commonStockIssued 35M 19M 0 8M 36M 0
commonStockRepurchased 0 0 0 0 0 0
dividendsPaid 0 0 0 0 0 0
otherFinancingActivites 35M 19M 0 0.000 268M 11M
netCashUsedProvidedByFinancingActivities 35M 19M 3M 8M 25M 11M
effectOfForexChangesOnCash 300 000 0 0 0 -1M 0
netChangeInCash -43M 134M 57M -159M 51M 49M
cashAtEndOfPeriod 259M 302M 168M 112M 271M 220M
cashAtBeginningOfPeriod 302M 168M 112M 271M 220M 171M
operatingCashFlow 124M 212M 180M -125M 143M 99M
capitalExpenditure -5M -8M -7M -9M -2M 0
freeCashFlow 118M 204M 173M -134M 141M 99M
link Link Link Link Link Link Link
finalLink Link Link Link Link Link Link

Earning call transcript

2023 q4
2024-02-07 ET (fiscal 2023 q4)
2023 q3
2023-10-31 ET (fiscal 2023 q3)
2023 q2
2023-08-01 ET (fiscal 2023 q2)
2023 q1
2023-05-03 ET (fiscal 2023 q1)
2022 q4
2023-02-06 ET (fiscal 2022 q4)
2022 q3
2022-11-01 ET (fiscal 2022 q3)
2022 q2
2022-08-04 ET (fiscal 2022 q2)
2022 q1
2022-05-04 ET (fiscal 2022 q1)

Press-releases

Show financial reports only

2024-02-07 12:00 ET
Neurocrine Biosciences Reports Fourth Quarter and Fiscal 2023 Financial Results and Provides Financial Expectations for 2024
2024-01-17 21:16 ET
Neurocrine Biosciences Announces Conference Call and Webcast of Fourth Quarter and Year-End 2023 Financial Results
2024-01-02 21:01 ET
Neurocrine Biosciences to Present at the 42nd Annual J.P. Morgan Healthcare Conference
2023-12-05 21:01 ET
Neurocrine Biosciences Receives Breakthrough Therapy Designation from U.S. Food and Drug Administration for Crinecerfont in Congenital Adrenal Hyperplasia
2023-12-01 12:00 ET
Neurocrine Biosciences to Host Analyst Day on December 5, 2023
2023-11-13 12:00 ET
Neurocrine Biosciences Announces Settlement of INGREZZA Abbreviated New Drug Application (ANDA) Litigation
2023-11-09 21:01 ET
Neurocrine Biosciences Provides Development Pipeline Update
2023-11-08 21:05 ET
Neurocrine Biosciences Launches Interactive Digital Tool for use by Healthcare Providers to Help Expand Education on Identifying and Diagnosing Tardive Dyskinesia
2023-11-08 21:01 ET
Neurocrine Biosciences to Present at the Jefferies London Healthcare Conference
2023-11-02 12:30 ET
Neurocrine Biosciences® Presents INGREZZA® (valbenazine) Capsules Interim Data Demonstrating Sustained Improvements in Chorea Associated With Huntington's Disease Through Week 50 at Huntington Study Group 2023
2023-10-31 11:00 ET
Neurocrine Biosciences Reports Third Quarter 2023 Financial Results and Raises 2023 INGREZZA Sales Guidance
2023-10-10 20:01 ET
Neurocrine Biosciences Announces Conference Call and Webcast of Third Quarter 2023 Financial Results
2023-10-05 11:00 ET
Neurocrine Biosciences Announces Phase 3 Pediatric Study Results of Crinecerfont in Children and Adolescents for the Treatment of Congenital Adrenal Hyperplasia Met Primary and Key Secondary Endpoints
2023-09-21 13:15 ET
Neurocrine Biosciences Presents Post Hoc Data Analysis in Congenital Adrenal Hyperplasia at ESPE 2023
2023-09-14 12:30 ET
Neurocrine Biosciences Announces U.S. FDA Accepts New Drug Application for INGREZZA® (valbenazine) Oral Granules Sprinkle Formulation
2023-09-12 11:30 ET
Neurocrine Biosciences Announces Positive Top-Line Data from Phase 3 Study of Crinecerfont in Adults for the Treatment of Congenital Adrenal Hyperplasia (CAH)
2023-09-11 23:01 ET
Sosei Heptares’ partner Neurocrine Biosciences Initiates Phase 1 Clinical Study Evaluating Effects of NBI-1117570 in Healthy Adults
2023-09-11 12:30 ET
Neurocrine Biosciences Announces Initiation of Phase 1 Clinical Study Evaluating Effects of NBI-1117570 in Healthy Adults
2023-08-31 20:01 ET
Neurocrine Biosciences to Present at Upcoming Investor Conferences in September
2023-08-29 12:30 ET
Neurocrine Biosciences Presents Data at MDS International Congress of Parkinson's Disease and Movement Disorders® Demonstrating Comparable Improvement Over Time in Tardive Dyskinesia Severity and Impact Following Treatment With INGREZZA® (valbenazine)...
2023-08-28 12:30 ET
Neurocrine Biosciences Presents New INGREZZA® (valbenazine) Capsules Data Demonstrating Early and Sustained Improvements in Chorea Associated With Huntington's Disease
2023-08-18 20:34 ET
Neurocrine Biosciences Announces FDA Approval of INGREZZA® (valbenazine) Capsules for the Treatment of Chorea Associated With Huntington's Disease
2023-08-01 11:00 ET
Neurocrine Biosciences Reports Second Quarter 2023 Financial Results and Raises 2023 INGREZZA Sales Guidance
2023-07-11 20:05 ET
Neurocrine Biosciences Announces Appointment of Christine A. Poon to Board of Directors
2023-07-11 20:01 ET
Neurocrine Biosciences Announces Conference Call and Webcast of Second Quarter 2023 Financial Results
2023-06-15 12:30 ET
Diurnal Ltd., a Neurocrine Biosciences Company, Presents Phase 3 Extension Study Data for Modified-Release Hydrocortisone in Patients with Congenital Adrenal Hyperplasia at ENDO 2023
2023-06-08 20:01 ET
Neurocrine Biosciences to Present at the Goldman Sachs 44th Annual Global Healthcare Conference
2023-06-02 12:30 ET
Neurocrine Biosciences Presents INGREZZA® (valbenazine) Capsules Data on Tardive Dyskinesia Improvement Regardless of Baseline Antipsychotic Use at 2023 Psych Congress Elevate
2023-05-19 12:30 ET
Neurocrine Biosciences Announces Publication of Full KINECT™-HD Phase 3 Study Results of Valbenazine for the Treatment of Chorea Associated with Huntington's Disease in The Lancet Neurology
2023-05-15 12:30 ET
Neurocrine Biosciences Presents INGREZZA® (valbenazine) Capsules Data on Long-Term Improvements and Psychiatric Stability in Patients With Tardive Dyskinesia and Schizophrenia or Schizoaffective Disorder at the Schizophrenia International Research Soc...
2023-05-12 12:30 ET
Neurocrine Biosciences Presents Data on Treatment of Patients with Congenital Adrenal Hyperplasia at ECE 2023
2023-05-03 11:30 ET
Neurocrine Biosciences Reports First Quarter 2023 Financial Results
2023-05-02 20:01 ET
Neurocrine Biosciences to Present at the Bank of America Securities 2023 Healthcare Conference
2023-05-01 12:30 ET
Neurocrine Biosciences Supports the Mental Health Community During Tardive Dyskinesia Awareness Week
2023-04-12 20:01 ET
Neurocrine Biosciences Announces Conference Call and Webcast of First Quarter 2023 Financial Results
2023-03-21 20:01 ET
Neurocrine Biosciences to Present at the Stifel 2023 CNS Days
2023-03-09 21:30 ET
Neurocrine Biosciences Announces Results from the Real-World RE-KINECT™ Study Published in the Journal of Patient-Reported Outcomes Demonstrating the Effects of Possible Tardive Dyskinesia (TD) on Patient Health and Social Functioning
2023-03-09 13:30 ET
Neurocrine Biosciences Presents Data on In Vitro Dissolution Performance of INGREZZA® (valbenazine) Capsule Contents via Soft Foods or Feeding Tube at AMDA - PALTC 2023 Annual Conference
2023-03-08 21:01 ET
Neurocrine Biosciences to Participate at Investor Conferences in March
2023-03-03 13:30 ET
Neurocrine Biosciences Presents Data on Improvements Over Time with Long-Term Use of INGREZZA® (valbenazine) Capsules in Older and Elderly Patients at the American Association for Geriatric Psychiatry 2023 Annual Meeting
2023-02-14 21:01 ET
Sentia Medical Sciences and Neurocrine Biosciences Extend Research Collaboration to Discover Novel CRF Peptides
2023-02-07 21:01 ET
Neurocrine Biosciences to Present at the SVB Securities Global Biopharma Conference
2023-02-06 12:30 ET
Neurocrine Biosciences Reports Fourth Quarter and Fiscal 2022 Financial Results and Provides Financial Expectations for 2023
2023-01-17 21:01 ET
Neurocrine Biosciences Announces Conference Call and Webcast of Fourth Quarter and Year-End 2022 Financial Results
2023-01-09 12:00 ET
Neurocrine Biosciences and Voyager Therapeutics Enter Strategic Collaboration for Development and Commercialization of Voyager’s GBA1 Program and Other Next-Generation Gene Therapies for Neurological Diseases
2023-01-03 21:01 ET
Neurocrine Biosciences to Present at the 41st Annual J.P. Morgan Healthcare Conference
2022-12-22 21:01 ET
Neurocrine Biosciences Announces U.S. FDA Accepts Supplemental New Drug Application for Valbenazine as a Treatment for Chorea Associated with Huntington Disease
2022-12-06 21:01 ET
Neurocrine Biosciences Provides Update on Phase 2 Study of NBI-827104 in Pediatric Patients with Epileptic Encephalopathy with Continuous Spike-and-Wave During Sleep
2022-12-02 13:30 ET
Neurocrine Biosciences Presents Demographic and Clinical Characteristics Data of Pediatric Patients with SCN8A-Related Epilepsies at AES 2022
2022-11-08 21:01 ET
Neurocrine Biosciences to Present at Upcoming Healthcare Conferences
2022-11-03 13:00 ET
Neurocrine Biosciences Presents Data on In Vitro Dissolution Performance of INGREZZA® (valbenazine) Capsules at the American Society of Consultant Pharmacists (ASCP) 2022 Annual Meeting
2022-11-03 12:30 ET
Neurocrine Biosciences Presents Additional Phase 3 Data for KINECT-HD Study Evaluating Valbenazine for Chorea Associated with Huntington Disease at HSG 2022
2022-11-01 11:30 ET
Neurocrine Biosciences Reports Third Quarter 2022 Financial Results and Raises 2022 INGREZZA Sales Guidance
2022-10-27 12:30 ET
Neurocrine Biosciences Initiates Phase 2 Clinical Study Evaluating NBI-1117568 in Adults with Schizophrenia
2022-10-24 12:30 ET
Neurocrine Biosciences Presents Real-World Parkinson's Disease Patient Characteristics From ONGENTYS® (opicapone) Open-Label Study at ANA2022
2022-10-19 12:30 ET
Neurocrine Biosciences Presents Data on Benztropine Use Among People Treated with Antipsychotics at the 2022 American Psychiatric Nurses Association (APNA) Annual Conference
2022-10-11 20:01 ET
Neurocrine Biosciences Announces Conference Call and Webcast of Third Quarter 2022 Financial Results
2022-09-29 15:00 ET
Neurocrine Biosciences Appoints Dr. Ingrid Delaet as Chief Regulatory Officer
2022-09-19 12:30 ET
Neurocrine Biosciences Presents INGREZZA® (valbenazine) Data on Sustained Treatment Response at Psych Congress 2022
2022-09-15 12:45 ET
Neurocrine Biosciences to Present Study Findings on Evolving Tardive Dyskinesia Education Needs of Physicians at the 2022 MDS International Congress
2022-09-15 12:30 ET
Neurocrine Biosciences Presents New Post-Hoc Analysis of ONGENTYS® (opicapone) Capsules Effect on COMT Activity at the 2022 MDS International Congress
2022-09-12 12:30 ET
Parkinson & Movement Disorder (PMD) Alliance and Neurocrine Biosciences Announce New Survey Results Revealing the Significant Impact OFF Time Has on People with Parkinson's Disease and Their Care Partners
2022-09-06 20:01 ET
Neurocrine Biosciences to Present at the Morgan Stanley 20th Annual Global Healthcare Conference
2022-08-04 23:05 ET
Sosei Heptares’ Oral, Selective M4 Receptor Agonist Advancing into Phase 2 Clinical Development under Multi-Program Collaboration with Neurocrine Biosciences
2022-08-04 20:01 ET
Neurocrine Biosciences Reports Second Quarter 2022 Financial Results and Raises 2022 INGREZZA Sales Guidance
2022-07-14 20:01 ET
Neurocrine Biosciences Announces Conference Call and Webcast of Second Quarter 2022 Financial Results
2022-06-13 12:00 ET
Neurocrine Biosciences Presents Data on Treatment of Adolescent Patients with Classic Congenital Adrenal Hyperplasia at ENDO 2022
2022-06-08 20:01 ET
Neurocrine Biosciences to Present at the Goldman Sachs 43rd Annual Global Healthcare Conference
2022-06-06 13:30 ET
Neurocrine Biosciences Honored at CARES Foundation 22nd Anniversary Gala
2022-06-06 12:30 ET
Neurocrine Biosciences Presents Data on Sleep Disturbances and OFF Time in Patients with Parkinson's Disease and Motor Fluctuations at SLEEP 2022
2022-05-25 01:40 ET
Neurocrine Biosciences Announces Repurchase of Convertible Notes
2022-05-23 12:30 ET
Neurocrine Biosciences Presents New INGREZZA® (valbenazine) Data on Tardive Dyskinesia Improvement and Stability of Psychiatric Symptoms at American Psychiatric Association Annual Meeting 2022
2022-05-12 23:37 ET
Neurocrine Biosciences Receives Orphan Drug Designation for Valbenazine as a Treatment for Chorea Associated with Huntington Disease
2022-05-04 11:30 ET
Neurocrine Biosciences Reports First Quarter 2022 Financial Results and Reiterates 2022 Financial Guidance
2022-05-03 20:01 ET
Neurocrine Biosciences to Present at the Bank of America Securities 2022 Healthcare Conference
2022-05-02 12:30 ET
Neurocrine Biosciences Honors Mental Health Awareness Month and Fifth Anniversary of Tardive Dyskinesia Awareness Week
2022-04-13 20:01 ET
Neurocrine Biosciences Announces Conference Call and Webcast of First Quarter 2022 Financial Results
2022-04-01 12:30 ET
Neurocrine Biosciences Presents Phase 3 Data for KINECT-HD Study Evaluating Valbenazine for Chorea Associated with Huntington Disease at AAN 2022
2022-03-28 20:36 ET
Neurocrine Biosciences Announces Regulatory Approval of Dysval® (valbenazine) for the Treatment of Tardive Dyskinesia in Japan
2022-03-28 12:30 ET
Neurocrine Biosciences to Present Data on Treatment Patterns and Unmet Needs in Adult and Pediatric Patients Living with Classic Congenital Adrenal Hyperplasia at AMCP 2022
2022-03-24 12:30 ET
Neurocrine Biosciences to Present Data from Movement Disorder Portfolio at the American Academy of Neurology 2022 In-Person and Virtual Annual Meeting
2022-03-21 20:01 ET
Neurocrine Biosciences to Present at Stifel 2022 CNS Days
2022-03-01 21:01 ET
Neurocrine Biosciences to Present at Upcoming Healthcare Conferences
2022-02-11 12:30 ET
Neurocrine Biosciences Reports Fourth Quarter and Fiscal 2021 Financial Results and Provides Financial Expectations for Fiscal 2022
2022-01-25 21:01 ET
Neurocrine Biosciences Announces Conference Call and Webcast of Fourth Quarter and Year-End 2021 Financial Results
2022-01-06 21:01 ET
Neurocrine Biosciences Provides Preliminary Fourth Quarter and Full-Year 2021 Net Product Sales Results and Future Program Milestones
2022-01-03 21:01 ET
Neurocrine Biosciences to Present at the 40th Annual J.P. Morgan Healthcare Conference
2021-12-07 21:35 ET
Neurocrine Biosciences Announces Positive Phase 3 Data for KINECT-HD Study Evaluating Valbenazine for Chorea Associated with Huntington Disease
2021-11-30 21:05 ET
Neurocrine Biosciences Appoints Jude Onyia, Ph.D., as Chief Scientific Officer
2021-11-22 13:00 ET
Neurocrine Biosciences and Sosei Heptares Announce Collaboration to Develop Novel Muscarinic Receptor Agonists for Schizophrenia and Other Neuropsychiatric Disorders
2021-11-09 21:01 ET
Neurocrine Biosciences to Present at Upcoming Healthcare Conferences
2021-11-01 20:01 ET
Neurocrine Biosciences Reports Third Quarter 2021 Financial Results
2021-11-01 12:00 ET
Neurocrine Biosciences Presents New INGREZZA® (valbenazine) Data at Psych Congress 2021
2021-10-16 21:00 ET
Neurocrine Biosciences to Present ONGENTYS® (opicapone) and INGREZZA® (valbenazine) Data at the American Neurological Association 2021 Virtual Annual Meeting
2021-10-11 20:01 ET
Neurocrine Biosciences Announces Conference Call and Webcast of Third Quarter 2021 Financial Results
2021-10-08 11:29 ET
Neurocrine Biosciences Expands Monumental Moments™ Program With World-Renowned Artist Jorge Rodriguez-Gerada to Raise Mental Health Awareness and Honor Those Impacted by the Pandemic
2021-09-10 13:23 ET
Neurocrine Biosciences to Present New INGREZZA® (valbenazine) and ONGENTYS® (opicapone) Data at the MDS Virtual Congress 2021
2021-09-08 12:30 ET
Xenon Pharmaceuticals Announces Collaboration with Neurocrine Biosciences Achieves $10.0 Million Regulatory Milestone
2021-09-02 20:13 ET
Neurocrine Biosciences to Present at Upcoming Healthcare Conferences
2021-08-05 20:01 ET
Neurocrine Biosciences Announces Completion of Enrollment in Phase 3 KINECT-HD Study Evaluating Valbenazine for Chorea in Huntington Disease
2021-08-03 20:01 ET
Neurocrine Biosciences Reports Second Quarter 2021 Financial Results
2021-07-19 20:01 ET
Neurocrine Biosciences Announces Conference Call and Webcast of Second Quarter 2021 Financial Results
2021-07-08 20:01 ET
Neurocrine Biosciences to Participate at the William Blair Biotech Focus Conference
2021-06-01 20:01 ET
Neurocrine Biosciences to Present at the Goldman Sachs 42nd Annual Global Healthcare Conference
2021-05-11 20:01 ET
Neurocrine Biosciences to Present at the 2021 RBC Global Healthcare Conference
2021-05-05 20:01 ET
Neurocrine Biosciences Reports First Quarter 2021 Financial Results
2021-05-04 20:01 ET
Neurocrine Biosciences to Present at the Bank of America 2021 Healthcare Conference
2021-05-03 12:30 ET
Neurocrine Biosciences Supports Mental Health Month and Tardive Dyskinesia Awareness Week
2021-04-26 20:01 ET
Sentia Medical Sciences and Neurocrine Biosciences Enter into Strategic Collaboration to Discover Novel CRF Peptides
2021-04-16 13:00 ET
Neurocrine Biosciences Announces Appointment of Johanna Mercier to Board of Directors
2021-04-14 20:01 ET
Neurocrine Biosciences Announces Conference Call and Webcast of First Quarter 2021 Financial Results
2021-04-08 20:01 ET
Neurocrine Biosciences to Present Data from its Neurology Portfolio at the American Academy of Neurology's 73rd 2021 Virtual Meeting
2021-03-25 20:01 ET
Neurocrine Biosciences to Present at Stifel 3rd Annual CNS Day
2021-03-24 22:35 ET
Neurocrine Biosciences Set to Join S&P MidCap 400; O-I Glass to Join S&P SmallCap 600
2021-03-20 15:00 ET
Neurocrine Biosciences to Present New Data Analyses for Crinecerfont in Adults with Classic Congenital Adrenal Hyperplasia at ENDO 2021
2021-03-09 21:01 ET
Neurocrine Biosciences to Present at the Oppenheimer 31st Annual Healthcare Conference
2021-03-02 12:30 ET
Neurocrine Biosciences Announces Top-Line Results from Phase II INTERACT Study Evaluating Luvadaxistat (NBI-1065844) for the Treatment of Negative Symptoms and Cognitive Impairment Associated with Schizophrenia (CIAS)
2021-02-23 21:01 ET
Neurocrine Biosciences to Present at the Cowen 41st Annual Health Care Conference
2021-02-04 21:01 ET
Neurocrine Biosciences Reports Fourth Quarter and Full-Year 2020 Financial Results
2021-02-02 21:01 ET
Voyager Therapeutics Provides Update on NBIb-1817 (VY-AADC) Gene Therapy Program
2021-01-20 21:01 ET
Neurocrine Biosciences Announces Conference Call and Webcast of Fourth Quarter and Year-End 2020 Financial Results
2021-01-08 12:30 ET
Neurocrine Biosciences Provides Preliminary Fourth Quarter and Full-Year 2020 Net Product Sales Results and 2021 Program Milestones
2021-01-04 21:01 ET
Neurocrine Biosciences to Present at the 39th Annual J.P. Morgan Healthcare Conference
2020-12-22 21:17 ET
Voyager Therapeutics Provides Update on NBIb-1817 (VY-AADC) Gene Therapy Program
2020-11-19 14:00 ET
Neurocrine Biosciences to Present at Upcoming Healthcare Conferences
2020-11-19 13:00 ET
Neurocrine Biosciences Announces Repurchase of Convertible Notes
2020-11-09 21:01 ET
Neurocrine Biosciences Reports Third Quarter 2020 Financial Results
2020-11-09 14:00 ET
Neurocrine Biosciences to Present at Upcoming Healthcare Conferences
2020-10-08 12:00 ET
Neurocrine Biosciences and Xenon Pharmaceuticals Provide Regulatory Update on Ongoing Collaboration to Develop First-In-Class Treatment for Epilepsy
2020-10-06 20:01 ET
Neurocrine Biosciences Announces Conference Call and Webcast of Third Quarter 2020 Financial Results
2020-09-28 20:01 ET
Neurocrine Biosciences to Present New Data Analyses of Once-Daily ONGENTYS® (opicapone) in Patients with Parkinson's Disease at the American Neurological Association 2020 Virtual Meeting
2020-09-14 12:44 ET
Neurocrine Biosciences Announces Once-Daily ONGENTYS® (opicapone) Now Available in the U.S. as an Add-On Treatment for Patients with Parkinson's Disease Experiencing "Off" Episodes
2020-09-11 15:36 ET
Neurocrine Biosciences and Voyager Therapeutics Present New Long-Term Three-Year Data Demonstrating that One-Time Treatment with an Investigational Gene Therapy Showed Sustained Improvement in Motor Function in Patients with Parkinson’s Disease
2020-09-11 15:34 ET
Neurocrine Biosciences Presents New Data Analyses Demonstrating Efficacy of FDA-Approved Once-Daily ONGENTYS® (opicapone) in Patients with Parkinson's Disease at the MDS Virtual Congress 2020
2020-09-11 15:32 ET
Neurocrine Biosciences and Voyager Therapeutics Present New Long-Term Three-Year Data Demonstrating that One-Time Treatment with an Investigational Gene Therapy Showed Sustained Improvement in Motor Function in Patients with Parkinson's Disease
2020-09-08 20:01 ET
Neurocrine Biosciences to Present at the Morgan Stanley 18th Annual Global Healthcare Conference
2020-09-03 20:06 ET
Neurocrine Biosciences to Present New Data from its Movement Disorder Programs for Tardive Dyskinesia and Parkinson's Disease at Upcoming Scientific Meetings
2020-09-02 20:01 ET
Neurocrine Biosciences to Present at the Citi 15th Annual BioPharma Virtual Conference
2020-08-03 20:01 ET
Neurocrine Biosciences Reports Second Quarter 2020 Financial Results
2020-07-30 20:01 ET
Neurocrine Biosciences to Participate at the William Blair Biotech Focus Conference 2020
2020-07-13 20:01 ET
Neurocrine Biosciences Announces Conference Call and Webcast of Second Quarter 2020 Financial Results
2020-06-16 11:00 ET
Neurocrine Biosciences and Takeda Announce Collaboration to Develop and Commercialize Potential Therapies for Psychiatric Disorders
2020-06-15 20:01 ET
Neurocrine Biosciences to Present at the Bank of America Securities 2020 Napa Biopharma Conference
2020-06-08 15:01 ET
/C O R R E C T I O N -- Neurocrine Biosciences, Inc./
2020-06-04 20:01 ET
Neurocrine Biosciences to Present at the Goldman Sachs 41st Annual Global Healthcare Conference Webcast
2020-05-26 20:01 ET
Neurocrine Biosciences to Present at the Jefferies Virtual Healthcare Conference
2020-05-14 23:29 ET
Neurocrine Biosciences to Present at the RBC Capital Markets 2020 Global Healthcare Conference
2020-05-13 20:01 ET
Neurocrine Biosciences to Present Data from its Movement Disorder Portfolio on the American Academy of Neurology Science Highlights Platform
2020-05-11 20:01 ET
Neurocrine Biosciences Exercises Option to License Idorsia's Novel Treatment for Rare Pediatric Epilepsy
2020-05-06 20:01 ET
Neurocrine Biosciences Reports First Quarter 2020 Financial Results
2020-05-05 20:01 ET
Neurocrine Biosciences to Present at Bank of America Merrill Lynch Health Care Conference 2020
2020-04-27 11:30 ET
Neurocrine Biosciences Announces FDA Approval of Once-Daily ONGENTYS® (opicapone) as an Add-On Treatment for Patients with Parkinson's Disease Experiencing "Off" Episodes
2020-04-15 20:01 ET
Neurocrine Biosciences Announces Conference Call and Webcast of First Quarter 2020 Financial Results
2020-04-03 12:30 ET
Neurocrine Biosciences Provides COVID-19 Business Update
2020-02-25 21:01 ET
Neurocrine Biosciences to Present at Cowen 40th Annual Health Care Conference
2020-02-04 21:01 ET
Neurocrine Biosciences Reports Fourth Quarter and Full-Year 2019 Financial Results
2020-02-03 22:00 ET
Neurocrine Biosciences Announces Appointment of Shalini Sharp to Board of Directors
2020-01-20 21:30 ET
Neurocrine Biosciences Announces Conference Call and Webcast of Fourth Quarter and Year-End 2019 Financial Results
2020-01-12 23:30 ET
Neurocrine Biosciences Provides Preliminary Fourth Quarter and Full-Year 2019 Net Product Sales Results and 2020 Program Milestones
2020-01-10 06:00 ET
Neurocrine Biosciences and Idorsia Amend Option Agreement to License Novel Treatment for Rare Pediatric Epilepsy
2020-01-06 21:01 ET
Neurocrine Biosciences to Present at the 38th Annual J.P. Morgan Healthcare Conference  Live Audio Webcast will be on January 13, 2020
2019-12-02 12:30 ET
Neurocrine Biosciences and Xenon Pharmaceuticals Announce Agreement to Develop First-in-Class Treatments for Epilepsy
2019-11-26 21:01 ET
Neurocrine Biosciences to Present at Evercore ISI 2nd Annual HealthCONx Conference
2019-11-12 21:01 ET
Neurocrine Biosciences Publishes Long-Term INGREZZA® (valbenazine) Data in the Journal of Clinical Psychopharmacology Demonstrating Once-Daily 40 mg and 80 mg Capsules Reduced Involuntary Movements in Adults with Tardive Dyskinesia
2019-11-05 21:01 ET
Neurocrine Biosciences to Present at Upcoming Healthcare Conferences
2019-11-04 21:01 ET
Neurocrine Biosciences Reports Third Quarter 2019 Financial Results
2019-10-14 20:01 ET
Neurocrine Biosciences Announces Conference Call and Webcast of Third Quarter 2019 Financial Results
2019-10-04 22:00 ET
Neurocrine Biosciences Presents New Data Analyses Demonstrating Long-Term Effects of INGREZZA® (valbenazine) 40 mg Once-Daily in Patients with Tardive Dyskinesia at the 2019 Annual Psych Congress
2019-10-01 20:01 ET
Neurocrine Biosciences to Present Data Analyses Demonstrating the Long-Term Effectiveness of INGREZZA® (valbenazine) in Patients with Tardive Dyskinesia at the 2019 Annual Psych Congress
2019-09-30 20:01 ET
Neurocrine Biosciences Appoints David W. Boyer as Chief Corporate Affairs Officer
2019-09-17 20:11 ET
Neurocrine Biosciences to Present Data on INGREZZA® (valbenazine) for Tardive Dyskinesia; Opicapone and VY-AADC for Parkinson's Disease, at the 2019 International Congress of Parkinson's Disease and Movement Disorders®
2019-09-11 20:01 ET
Neurocrine Biosciences Announces Appointment of Leslie V. Norwalk to Board of Directors
2019-08-28 20:01 ET
Neurocrine Biosciences to Present at Upcoming Healthcare Conferences
2019-08-05 12:30 ET
AbbVie Submits New Drug Application to US FDA for Investigational Elagolix for Management of Heavy Menstrual Bleeding Associated with Uterine Fibroids in Women
2019-07-29 20:01 ET
Neurocrine Biosciences Reports Second Quarter 2019 Financial Results
2019-07-10 20:10 ET
Neurocrine Biosciences Announces FDA Acceptance of New Drug Application for Opicapone as an Adjunctive Treatment for Patients with Parkinson's Disease
2019-07-08 20:01 ET
Neurocrine Biosciences Announces Conference Call and Webcast of Second Quarter 2019 Financial Results
2019-06-11 20:01 ET
Neurocrine Biosciences to Present Data on INGREZZA® (valbenazine) and Opicapone at the 2019 World Congress on Parkinson's Disease and Related Disorders
2019-06-04 20:01 ET
Neurocrine Biosciences to Present at Goldman Sachs 40th Annual Global Healthcare Conference
2019-05-30 20:01 ET
Neurocrine Biosciences to Present at Jefferies 2019 Global Healthcare Conference
2019-05-16 20:01 ET
Neurocrine Biosciences to Present New Quality-of-Life Data Analysis from RE-KINECT, the Largest Real-World Screening Study of Possible Tardive Dyskinesia Patients, at the 2019 American Psychiatric Association Annual Meeting
2019-05-06 12:00 ET
Neurocrine Biosciences Honors Mental Health Month and Raises Awareness of Tardive Dyskinesia and its Impact on Patients
2019-05-05 13:05 ET
Neurocrine Biosciences and Voyager Therapeutics Announce Phase I Results for VY-AADC in Patients with Parkinson's Disease at the American Academy of Neurology Annual Meeting
2019-05-05 13:00 ET
Neurocrine Biosciences Presents Phase III Data Analysis Demonstrating that Opicapone Added to Levodopa Resulted in a Significant and Sustained Increase in ON Time without Troublesome Dyskinesia in Parkinson's Disease Patients with Motor Fluctuations
2019-04-29 20:01 ET
Neurocrine Biosciences Reports First Quarter 2019 Financial Results
2019-04-08 20:01 ET
Neurocrine Biosciences Announces Conference Call and Webcast of First Quarter 2019 Financial Results
2019-03-28 20:15 ET
Neurocrine Biosciences and Voyager Therapeutics Announce Publication of Phase 1b Trial Results of VY-AADC for Parkinson’s Disease in the Annals of Neurology
2019-01-29 12:00 ET
Neurocrine Biosciences and Voyager Therapeutics Form Strategic Development and Commercialization Collaboration for Parkinson’s Disease and Friedreich’s Ataxia

SEC forms

Show financial reports only

SEC form 10
2024-02-09 00:00 ET
Neurocrine Biosciences reported for 2023 q4
SEC form 8
2024-02-07 00:00 ET
Neurocrine Biosciences published news for 2023 q4
SEC form 8
2024-02-07 00:00 ET
Neurocrine Biosciences published news for 2023 q4
SEC form 10
2023-10-31 07:02 ET
Neurocrine Biosciences reported for 2023 q3
SEC form 8
2023-10-31 07:01 ET
Neurocrine Biosciences published news for 2023 q3
SEC form 10
2023-10-31 00:00 ET
Neurocrine Biosciences published news for 2023 q3
SEC form 10
2023-08-01 07:03 ET
Neurocrine Biosciences reported for 2023 q2
SEC form 6
2023-08-01 07:02 ET
Neurocrine Biosciences published news for 2023 q2
SEC form 10
2023-08-01 00:00 ET
Neurocrine Biosciences published news for 2023 q2
SEC form 8
2023-08-01 00:00 ET
Neurocrine Biosciences published news for 2023 q2
SEC form 6
2023-07-13 17:26 ET
Neurocrine Biosciences published news for 2023 q2
SEC form 6
2023-07-13 16:05 ET
Neurocrine Biosciences published news for 2023 q2
SEC form 6
2023-07-11 19:04 ET
Neurocrine Biosciences published news for 2023 q2
SEC form 8
2023-05-03 00:00 ET
Neurocrine Biosciences published news for 2023 q1
SEC form 10
2023-05-03 00:00 ET
Neurocrine Biosciences published news for 2023 q1
SEC form 6
2023-03-28 20:44 ET
Neurocrine Biosciences published news for 2022 q4
SEC form 6
2023-02-23 19:14 ET
Neurocrine Biosciences published news for 2022 q4
SEC form 6
2023-02-15 19:30 ET
Neurocrine Biosciences published news for 2022 q4
SEC form 6
2023-02-10 16:02 ET
Neurocrine Biosciences published news for 2022 q4
SEC form 10
2023-02-09 16:02 ET
Neurocrine Biosciences reported for 2022 q4
SEC form 10
2023-02-09 00:00 ET
Neurocrine Biosciences reported for 2022 q4
SEC form 6
2023-02-06 07:32 ET
Neurocrine Biosciences published news for 2022 q4
SEC form 8
2023-02-06 00:00 ET
Neurocrine Biosciences reported for 2022 q4
SEC form 6
2023-01-09 07:04 ET
Neurocrine Biosciences published news for 2022 q4
SEC form 10
2022-11-01 16:10 ET
Neurocrine Biosciences reported for 2022 q3
SEC form 6
2022-11-01 07:31 ET
Neurocrine Biosciences published news for 2022 q3
SEC form 8
2022-11-01 00:00 ET
Neurocrine Biosciences reported for 2022 q3
SEC form 10
2022-11-01 00:00 ET
Neurocrine Biosciences reported for 2022 q3
SEC form 6
2022-08-30 08:01 ET
Neurocrine Biosciences published news for 2022 q2
SEC form 10
2022-08-04 16:08 ET
Neurocrine Biosciences reported for 2022 q2
SEC form 6
2022-08-04 16:05 ET
Neurocrine Biosciences published news for 2022 q2
SEC form 8
2022-08-04 00:00 ET
Neurocrine Biosciences reported for 2022 q2
SEC form 10
2022-08-04 00:00 ET
Neurocrine Biosciences reported for 2022 q2
SEC form 6
2022-05-31 21:04 ET
Neurocrine Biosciences published news for 2022 q1
SEC form 6
2022-05-24 21:44 ET
Neurocrine Biosciences published news for 2022 q1
SEC form 6
2022-05-23 16:17 ET
Neurocrine Biosciences published news for 2022 q1
SEC form 10
2022-05-04 07:39 ET
Neurocrine Biosciences reported for 2022 q1
SEC form 6
2022-05-04 07:37 ET
Neurocrine Biosciences published news for 2022 q1
SEC form 8
2022-05-04 00:00 ET
Neurocrine Biosciences reported for 2022 q1
SEC form 10
2022-05-04 00:00 ET
Neurocrine Biosciences reported for 2022 q1
SEC form 6
2022-04-07 17:16 ET
Neurocrine Biosciences published news for 2022 q1
SEC form 10
2022-02-11 17:11 ET
Neurocrine Biosciences published news for 2021 q4
SEC form 6
2022-02-11 07:31 ET
Neurocrine Biosciences published news for 2021 q4
SEC form 10
2022-02-11 00:00 ET
Neurocrine Biosciences published news for 2021 q4
SEC form 8
2022-02-11 00:00 ET
Neurocrine Biosciences published news for 2021 q4
SEC form 6
2022-02-09 20:01 ET
Neurocrine Biosciences published news for 2021 q4
SEC form 6
2022-01-06 16:08 ET
Neurocrine Biosciences published news for 2021 q4
SEC form 8
2022-01-06 00:00 ET
Neurocrine Biosciences published news for 2021 q4
SEC form 6
2021-12-23 08:00 ET
Neurocrine Biosciences published news for 2021 q3
SEC form 6
2021-12-01 19:56 ET
Neurocrine Biosciences published news for 2021 q3
SEC form 6
2021-11-22 08:01 ET
Neurocrine Biosciences published news for 2021 q3
SEC form 10
2021-11-01 16:05 ET
Neurocrine Biosciences published news for 2021 q3
SEC form 6
2021-11-01 16:03 ET
Neurocrine Biosciences published news for 2021 q3
SEC form 10
2021-11-01 00:00 ET
Neurocrine Biosciences published news for 2021 q3
SEC form 8
2021-11-01 00:00 ET
Neurocrine Biosciences published news for 2021 q3
SEC form 10
2021-08-03 16:03 ET
Neurocrine Biosciences published news for 2021 q2
SEC form 6
2021-08-03 16:02 ET
Neurocrine Biosciences published news for 2021 q2
SEC form 8
2021-08-03 00:00 ET
Neurocrine Biosciences published news for 2021 q2
SEC form 10
2021-08-03 00:00 ET
Neurocrine Biosciences published news for 2021 q2
SEC form 6
2021-05-21 16:03 ET
Neurocrine Biosciences published news for 2021 q1
SEC form 10
2021-05-05 16:07 ET
Neurocrine Biosciences published news for 2021 q1
SEC form 6
2021-05-05 16:05 ET
Neurocrine Biosciences published news for 2021 q1
SEC form 8
2021-05-05 00:00 ET
Neurocrine Biosciences published news for 2021 q1
SEC form 10
2021-05-05 00:00 ET
Neurocrine Biosciences published news for 2021 q1
SEC form 6
2021-04-16 16:02 ET
Neurocrine Biosciences published news for 2021 q1
SEC form 6
2021-04-16 09:02 ET
Neurocrine Biosciences published news for 2021 q1
SEC form 6
2021-04-09 17:07 ET
Neurocrine Biosciences published news for 2021 q1
SEC form 10
2021-02-05 16:19 ET
Neurocrine Biosciences published news for 2020 q4
SEC form 6
2021-02-04 16:05 ET
Neurocrine Biosciences published news for 2020 q4
SEC form 6
2021-02-02 16:04 ET
Neurocrine Biosciences published news for 2020 q4
SEC form 6
2021-01-08 07:32 ET
Neurocrine Biosciences published news for 2020 q4
SEC form 6
2020-11-24 08:02 ET
Neurocrine Biosciences published news for 2020 q3
SEC form 6
2020-11-19 08:07 ET
Neurocrine Biosciences published news for 2020 q3
SEC form 10
2020-11-09 16:04 ET
Neurocrine Biosciences published news for 2020 q3
SEC form 6
2020-11-09 16:02 ET
Neurocrine Biosciences published news for 2020 q3